SecBot SecBot

NAMSW

NewAmsterdam Pharma Co N.V.
Nasdaq· Pharmaceutical Preparations· Inc. P7· CIK 0001936258 Biotech & Drug Discovery
Warrants of NewAmsterdam Pharma Co N.V. · NAMS stock page →
$9.49 +0.00 (+0.00%)
Nov 16 4:00 PM ET · prev $9.49
Market cap
$1.1B
Small cap
1 year
−66.5%
from $28.32 · Nov 17
30 days
+5.4%
from $9.00
52-week range
$7.31–29.99
−68% from high · low Nov 9
Avg volume 20D
1.4K
Nov 2 spike 15.4K
Short interest
61
≈0.0% of shares · +45.2%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 3 reports · latest
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersBUILDING

    Short interest +45.2% to 61 shares. 1.0 days to cover, ≈0.0% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
WOLVERINE ASSET MANAGEMENT LLCDOUBLED14,925$318.9K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
61
shares short
+45.2%
vs prior settlement
1.0
days to cover
≈0.0%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 6, 2026
Press release
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the…
Nov 4, 2026
Earnings
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination)…
Oct 2, 2026
Press release
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the…
Sep 21, 2026
Press release
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable…
Sep 3, 2026
Press release
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the…

SecBot reports

3 filings · 1 bullish · 0 bearish · 2 neutral
All NAMSW filing & press-release reports (3)